https://www.thebodypro.com/category/cobicistat-tybost

Cobicistat (Tybost)

The Latest

An Overview of Tybost (Cobicistat) Img

An Overview of Tybost (Cobicistat)

Brand Name: Tybost Other Names: COBI Drug Class: Pharmacokinetic enhancers (CYP3A inhibitors)

Doctors Report Interaction Between Cobicistat and Tacrolimus Img
News

Doctors Report Interaction Between Cobicistat and Tacrolimus

A team in Chicago recently reported an interaction between cobicistat and the transplant medicine tacrolimus (Advagraf, Prograf) in a person taking Stribild, and cautioned others to be mindful of the potential for interaction between these drugs.

New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless ... Img
News

New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless ...

"If you're wondering what the big deal is [about the approvals of stand-alone cobicistat and elvitegravir], welcome to the club," Paul Sax, M.D., writes.

Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved as Individual HIV Drugs Img
News

Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved as Individual HIV Drugs

With this approval, each component of the single-tablet regimen Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) is now green-lighted for use separately in HIV treatment regimens in the U.S.

Promo Image
News

FDA Approval Notice for Tybost (Cobicistat)

On September 24, 2014, FDA approved Tybost (cobicistat) 150 mg tablets. Tybost is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the ...

Promo Image
News

Cobicistat Approved as Pharmacokinetic (PK) Booster for Atazanavir and Darunavir in EU Prior to the U.S.

On 25 September 2013, Gilead announced that its pharmacokinetic booster cobicistat had been approved in Europe with an indication to boost once-daily use of either atazanavir (300 mg) or darunavir (800 mg), in combination with other ARVs in a combina...

Promo Image
News

Gilead Receives Complete Response Letters From U.S. FDA for Elvitegravir and Cobicistat

Foster City, Calif. (Business Wire) -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has received Complete Response Letters from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for elvitegravir...

Promo Image
News

Tibotec and Gilead Team Up to Develop Prezista/Cobicistat Combo

Tibotec Pharmaceuticals announced on June 28 that it has entered into a license agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily, single-tablet, fixed dose antiretroviral combination product containin...